Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis

Uruga, Hironori; Kishi, Kazuma; Fujii, Takeshi; Beika, Yuka; Enomoto, Takahiro; Takaya, Hisashi; Miyamoto, Atsushi; Morokawa, Nasa; Kurosaki, Atsuko; Yoshimura, Kazuya

doi:10.2169/internalmedicine.49.2531

Cited by 30 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Major grade 3 AEs were skin rash (12 %) and hepatic dysfunction (18 %). Comparable results were also obtained by Uruga and colleagues in another small Japanese study including nine elderly (aged C70 years) EGFRmutant NSCLC patients treated with gefitinib [54]. In 2013, Tateishi et al confirmed the strong activity and the favourable safety profile of gefitinib in a retrospective analysis among 55 chemotherapy-naïve EGFR mut?…”

Section: Egfr-tkis In Elderly Egfr Mut1 Nsclc Patientsmentioning

confidence: 60%

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

2015

View full text Add to dashboard Cite

The elderly population with cancer is increasing worldwide. Currently, the median age at lung cancer diagnosis is approximately 70 years. Clinicians are increasingly dealing with a population of elderly non-small-cell lung cancer patients characterised by relevant co-morbidities and ageing-related characteristics, making treatment choice more challenging. Robust evidence demonstrated that activating mutations in the epidermal growth factor receptor (EGFR) gene are the best predictor for sensitivity to EGFR tyrosine kinase inhibitors. Nine large phase III trials conducted in both the Asian and Caucasian populations demonstrated that gefitinib, erlotinib and afatinib are superior to standard platinum-based chemotherapy as front-line treatment and subgroup analyses confirmed the superiority of erlotinib or gefitinib over chemotherapy in the second-line setting. Although no large phase III trials have been specifically conducted in EGFR mutation-positive (EGFR (mut+)) elderly non-small-cell lung cancer patients, available data, coming from subgroup analysis, retrospective series or small prospective phase II trials, replicated in the elderly the results observed in the general population, thus suggesting that age per se does not represent a criterion for treatment selection. In addition, the favourable toxicity profile of EGFR-tyrosine kinase inhibitors makes these agents the preferred option in such a group of patients, for which concomitant medications are often required.

show abstract

Section: Egfr-tkis In Elderly Egfr Mut1 Nsclc Patientsmentioning

confidence: 60%

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

2015

View full text Add to dashboard Cite

show abstract

“…For mutation detection, Sanger sequencing has been widely utilized and still serves as a gold standard in most clinical laboratories, but lower sensitivity limited its utility [23,24].…”

Section: Discussionmentioning

confidence: 99%

Sensitive detection of trace amounts of KRAS codon 12 mutations by a fast and novel one-step technique

Xie

Huang

et al. 2014

Clinical Biochemistry

View full text Add to dashboard Cite

“…Sequencing is a straightforward method and is widely used [27][28][29]. However, the detection limit for direct sequencing is generally about 25-30% mutant alleles of total genomic DNA content [12,30].…”

Section: Discussionmentioning

confidence: 99%

A novel method for detection of mutation in epidermal growth factor receptor

Zhao¹,

Zhao²,

Huang³

et al. 2011

Lung Cancer

View full text Add to dashboard Cite

Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis

Abstract: Gefitinib is very efficacious and safe for elderly patients with adenocarcinoma of the lung harboring an EGFR tyrosine kinase mutation. The present data support the use of gefitinib in this particular subgroup.

Cited by 30 publications

References 20 publications

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

Sensitive detection of trace amounts of KRAS codon 12 mutations by a fast and novel one-step technique

A novel method for detection of mutation in epidermal growth factor receptor

Contact Info

Product

Resources

About